[1]江文辉,温江妹.母细胞样套细胞淋巴瘤1例[J].福建医药杂志,2024,46(04):179-180.[doi:10.20148/j.fmj.2024.04.060]
点击复制

母细胞样套细胞淋巴瘤1例()
分享到:

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年04期
页码:
179-180
栏目:
病例报告
出版日期:
2024-08-15

文章信息/Info

作者:
江文辉温江妹
福建省龙岩市第二医院病理科,龙岩 364215
DOI:
10.20148/j.fmj.2024.04.060

参考文献/References:

[1] OINONEN R,FRANSSILA K,TEERENHOVI L,et al. Mantle cell lymphoma:clinical features,treatment and prognosis of 94 patients[J].European Journal of Cancer,1998,34(3):329-336.
[2] SABATTINI E,BACCI F,SAGRAMOSO C,et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica,2010,102(3): 83-87.
[3] VOSE J M. Mantle cell lymphoma:2017 update on diagnosis,risk-stratification,and clinical management[J].American Journal of Hematology,2017,92(8):806-813.
[4] KLEIHUES P,SOBIN L H. World Health Organization classification of tumors[J].Cancer,2000,88(12):2887.
[5] BERTONI F,PONZONI M. The cellular origin of mantle cell lymphoma[J].Int J Biochem Cell Biol,2007,39(10):1747-1753.
[6] MIAO Y,LIN P,SAKSENA A,et al. CD5-negative mantle cell lymphoma: clinicopathologic correlations and outcome in 58 patients[J].Am J Surg Pathol,2019,43(8):1052-1060.
[7] ROBAK T,HUANG H Q,JIN J,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma[J].New England Journal of Medicine,2015,372(10):944-953.
[8] MADDOCKS K,CHRISTIAN B,JAGLOWSKI S,et al. A phase 1/1b study of rituximab,bendamustine,and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma[J].Blood,2015,125(2):242-248.

更新日期/Last Update: 2024-08-15